Eye-tracking as a potential biomarker for autism

Eye-tracking as a potential biomarker for autism

The Autism Biomarkers Consortium for Clinical Trials is a multisite study specifically designed to evaluate a set of promising electrophysiological and eye-tracking (ET) methodologies as candidate biomarkers for autism spectrum disorder (ASD). ET task uses pupillary reflex measurements and gaze monitoring under different visual tasks, to identify specific features associated with ASD. Two recent publications from the ABC-CT [1, 2] report on the progress made in evaluating ET. Pilot studies and a pivotal study that enrolled 200 children with ASD and 75 children with typical development between 6 and 11 years old have determined that ET is a good candidate for a biomarker for ASD.

Based on these findings, the consortium has sent a letter of intent to the FDA to solicit feedback regarding the potential viability of the ‘ET Oculomotor Index’ as a diagnostic biomarker. Autism diagnosis is severely hampered by the lack of objective screening tools and/or biomarkers. Adopting ET as an objective, sensitive and reliable biomarker will significantly impact diagnosis and monitoring of progression.

Contact us now for a free demonstration 1-800-895-7405.
References:

1 McPartland JC, et al., The Autism Biomarkers Consortium for Clinical Trials (ABC-CT): Scientific Context, Study Design, and Progress Toward Biomarker Qualification. Front Integr Neurosci. 2020 Apr 9;14:16. doi: 10.3389/fnint.2020.00016.

2 Webb SJ, Shic F, Murias M, et al. Biomarker Acquisition and Quality Control for Multi-Site Studies: The Autism Biomarkers Consortium for Clinical Trials. Front Integr Neurosci. 2020;13:71. Published 2020 Feb 7. doi:10.3389/fnint.2019.00071.